Stocktoria
Vistagen Therapeutics, Inc. VTGN
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2010-10-18
Vistagen Therapeutics, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Operating margin | -5683.7% | -11517.1% | -3103.5% | 26109.3% | -4308.3% |
| Net margin | -5491.3% | -10579.8% | -2759.6% | 26100.4% | -4306.8% |
| FCF margin | — | — | — | — | -4098.9% |
| Return on assets | -143.5% | -61.0% | -23.7% | -280.9% | -64.0% |
| Return on equity | -196.2% | -73.0% | -25.7% | -490.5% | -73.8% |
| Current ratio | 3.67 | 6.51 | 23.55 | 3.83 | 12.32 |
| Revenue growth | 161.1% | -54.3% | -568.7% | -120.5% | 1.8% |
Source: SEC EDGAR filings · CIK 0001411685 · as of 2026-03-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.